Senti Biosciences Holdings
SNTI
22 hedge funds and large institutions have $44.4M invested in Senti Biosciences Holdings in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 34 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.45% less ownership
Funds ownership: 7.69% → 3.24% (-4.4%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
51% less funds holding
Funds holding: 45 → 22 (-23)
68% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 34
75% less capital invested
Capital invested by funds: $180M → $44.4M (-$136M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$35.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$6.08M |
| 4 |
IC
Intel Corp
Santa Clara,
California
|
+$4.78M |
| 5 |
AG
Artal Group
Luxembourg
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$19.7M |
| 2 |
SC
Sculptor Capital
New York
|
-$15.2M |
| 3 |
Morgan Stanley
New York
|
-$11.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$9.34M |
| 5 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$7.68M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
51
HRT Financial
New York
| – | -$290K | -2,938 | Closed |
|
|
RCM
52
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| – | -$206K | -2,089 | Closed |
|
|
OAC
53
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$168K | -1,701 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$17.2K | -214 | -100% |
|
55
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$1K | -8 | Closed |
|
|
CS
56
Clear Street
New York
| – | +$80 | +1 | New |
|
SNTI Hedge Fund Activity: Q2 2022 in Review
22 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q2 2022, worth a combined $44.4M — down 75% from $180M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of SNTI and 11 opened new positions — a net loss of 23 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was NEA Management Company, opening a new position worth an estimated $35.6M. The largest seller was Woodline Partners, exiting entirely with an estimated $19.7M sold.
- 22 institutional investors held Senti Biosciences Holdings (SNTI) as of Q2 2022, down from 45 in Q1 2022.
- Funds reported $44.4M of Senti Biosciences Holdings stock for Q2 2022, down 75% quarter-over-quarter.
- 11 funds opened new Senti Biosciences Holdings positions in Q2 2022 and 34 closed out, a net change of -23 holders.
- The largest Senti Biosciences Holdings buyer in Q2 2022 was NEA Management Company, an estimated $35.6M added.
- The largest Senti Biosciences Holdings seller in Q2 2022 was Woodline Partners, an estimated $19.7M sold.
Based on aggregated 13F filings for Q2 2022.